☆ 4.7 Letter

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S. Smolen et al.

Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Editorial Material Medicine, General & Internal

Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases

Jeffrey R. Curtis et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission The ARCTIC REWIND Randomized Clinical Trial

Siri Lillegraven et al.

Summary: In patients with rheumatoid arthritis in remission taking csDMARD therapy, treatment with half-dose compared to stable-dose csDMARDs resulted in higher disease flares over 12 months, failing to meet the noninferiority criterion. There were significantly fewer flares in the stable-dose group, indicating that half-dose therapy may not be as effective for these patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Review Rheumatology

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability

M. Verstappen et al.

RMD OPEN (2020)

添加到收藏夹

Article Rheumatology

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study

Judith Haschka et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

添加到收藏夹

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

相关参考文献

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission The ARCTIC REWIND Randomized Clinical Trial

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study

导出引文

分享论文